达托霉素（LY146032）和帕地霉素（U-70,138F）对厌氧革兰氏阳性菌的体外活性。
In vitro activities of daptomycin (LY146032) and paldimycin (U-70,138F) against anaerobic gram-positive bacteria.
作者信息
Chow A W, Cheng N
机构信息
Department of Medicine, University of British Columbia, Vancouver, Canada.
出版信息
Antimicrob Agents Chemother. 1988 May;32(5):788-90. doi: 10.1128/AAC.32.5.788.
Abstract
The in vitro activities of daptomycin (LY146032), paldimycin (U-70,138F), vancomycin, and penicillin G against 344 clinical isolates of anaerobic gram-positive bacteria were determined by an agar dilution method in calcium-supplemented (50 micrograms/ml) Wilkins-Chalgren medium, using an inoculum of 10(5) CFU. Daptomycin demonstrated excellent activity against a broad range of anaerobic gram-positive cocci and bacilli, including Peptostreptococcus, Eubacterium, Bifidobacterium, Actinomyces, Propionibacterium, and Lactobacillus species and Clostridium difficile. Highly resistant strains (MIC, greater than or equal to 64 micrograms/ml) were encountered sporadically from different genera, but these accounted for only 3% of all isolates tested. Vancomycin showed similar activity but was less active against Lactobacillus species and Peptostreptococcus prevotii. Paldimycin was inactive against most genera of anaerobic gram-positive bacteria. Overall, penicillin G remained the most broadly active agent against these isolates.
摘要
采用琼脂稀释法，在添加钙（50微克/毫升）的威尔金斯-查尔格伦培养基中，以10⁵CFU的接种量，测定了达托霉素（LY146032）、帕地霉素（U-70,138F）、万古霉素和青霉素G对344株厌氧革兰氏阳性菌临床分离株的体外活性。达托霉素对多种厌氧革兰氏阳性球菌和杆菌表现出优异活性，包括消化链球菌属、优杆菌属、双歧杆菌属、放线菌属、丙酸杆菌属、乳酸杆菌属菌种以及艰难梭菌。不同菌属偶尔会出现高耐药菌株（MIC≥64微克/毫升），但这些仅占所有测试分离株的3%。万古霉素表现出类似活性，但对乳酸杆菌属菌种和普氏消化链球菌活性较低。帕地霉素对大多数厌氧革兰氏阳性菌属无活性。总体而言，青霉素G仍是对这些分离株活性最广泛的药物。
相似文献
1
In vitro activities of daptomycin (LY146032) and paldimycin (U-70,138F) against anaerobic gram-positive bacteria.达托霉素（LY146032）和帕地霉素（U-70,138F）对厌氧革兰氏阳性菌的体外活性。
Antimicrob Agents Chemother. 1988 May;32(5):788-90. doi: 10.1128/AAC.32.5.788.
2
Comparative activity of LY146032 against anaerobic cocci.LY146032对厌氧球菌的比较活性。
Eur J Clin Microbiol. 1987 Dec;6(6):682-4. doi: 10.1007/BF02013071.
3
In vitro activities of daptomycin, vancomycin, quinupristin- dalfopristin, linezolid, and five other antimicrobials against 307 gram-positive anaerobic and 31 Corynebacterium clinical isolates.达托霉素、万古霉素、奎奴普丁-达福普汀、利奈唑胺及其他五种抗菌药物对307株革兰氏阳性厌氧菌和31株棒状杆菌临床分离株的体外活性。
Antimicrob Agents Chemother. 2003 Jan;47(1):337-41. doi: 10.1128/AAC.47.1.337-341.2003.
4
In vitro activities of the new semisynthetic glycopeptide telavancin (TD-6424), vancomycin, daptomycin, linezolid, and four comparator agents against anaerobic gram-positive species and Corynebacterium spp.新型半合成糖肽类药物特拉万星（TD-6424）、万古霉素、达托霉素、利奈唑胺以及四种对照药物对厌氧革兰氏阳性菌和棒状杆菌属的体外活性
Antimicrob Agents Chemother. 2004 Jun;48(6):2149-52. doi: 10.1128/AAC.48.6.2149-2152.2004.
5
In vitro activities of dalbavancin and nine comparator agents against anaerobic gram-positive species and corynebacteria.达巴万星及九种对照药物对厌氧革兰氏阳性菌和棒状杆菌的体外活性。
Antimicrob Agents Chemother. 2003 Jun;47(6):1968-71. doi: 10.1128/AAC.47.6.1968-1971.2003.
6
Comparative in vitro activity of LY146032 (daptomycin), a new lipopeptide antimicrobial.新型脂肽类抗菌药物LY146032（达托霉素）的体外活性比较
Eur J Clin Microbiol. 1987 Feb;6(1):100-3. doi: 10.1007/BF02097211.
7
Comparative in-vitro activity of LY146032 a new peptolide, with vancomycin and eight other agents against gram-positive organisms.新型缩肽类抗生素LY146032与万古霉素及其他八种药物对革兰氏阳性菌的体外活性比较
J Antimicrob Chemother. 1987 Aug;20(2):191-6. doi: 10.1093/jac/20.2.191.
8
In vitro evaluation of the new paulomycin antibiotic paldimycin.新型保洛霉素类抗生素帕地霉素的体外评价
Eur J Clin Microbiol. 1987 Jun;6(3):306-8. doi: 10.1007/BF02017620.
9
In vitro activity of vancomycin and teicoplanin against anaerobic bacteria.万古霉素和替考拉宁对厌氧菌的体外活性。
Drugs Exp Clin Res. 1987;13(9):551-4.
10
In vitro activity of TD-1792, a multivalent glycopeptide-cephalosporin antibiotic, against 377 strains of anaerobic bacteria and 34 strains of Corynebacterium species.TD-1792 体外活性研究，一种多价糖肽-头孢菌素抗生素，针对 377 株厌氧菌和 34 株棒状杆菌属细菌。
Antimicrob Agents Chemother. 2012 Apr;56(4):2194-7. doi: 10.1128/AAC.06274-11. Epub 2012 Jan 30.
引用本文的文献
1
Pioneer colonizers: Bacteria that alter the chicken intestinal morphology and development of the microbiota.先锋定植菌：改变鸡肠道形态和微生物群发育的细菌。
Front Physiol. 2023 Mar 29;14:1139321. doi: 10.3389/fphys.2023.1139321. eCollection 2023.
2
Diagnosis?诊断结果是什么？
Can J Infect Dis. 1995 Sep;6(5):243-65. doi: 10.1155/1995/238265.
3
The potential of antimicrobial peptides as biocides.抗菌肽作为生物杀灭剂的潜力。
Int J Mol Sci. 2011;12(10):6566-96. doi: 10.3390/ijms12106566. Epub 2011 Oct 6.
4
Altered growth, pigmentation, and antimicrobial susceptibility properties of Staphylococcus aureus due to loss of the major cold shock gene cspB.由于主要冷休克基因 cspB 的缺失，金黄色葡萄球菌的生长、色素沉着和抗菌敏感性特性发生改变。
Antimicrob Agents Chemother. 2010 Jun;54(6):2283-90. doi: 10.1128/AAC.01786-09. Epub 2010 Apr 5.
5
Propionibacterium acnes as a cause of prosthetic valve aortic root abscess.痤疮丙酸杆菌作为人工瓣膜主动脉根部脓肿的病因。
J Clin Microbiol. 2007 Jan;45(1):259-61. doi: 10.1128/JCM.01598-06. Epub 2006 Oct 25.
6
In vitro activities of daptomycin, vancomycin, and penicillin against Clostridium difficile, C. perfringens, Finegoldia magna, and Propionibacterium acnes.达托霉素、万古霉素和青霉素对艰难梭菌、产气荚膜梭菌、大芬戈尔德菌和痤疮丙酸杆菌的体外活性。
Antimicrob Agents Chemother. 2006 Aug;50(8):2728-31. doi: 10.1128/AAC.00357-06.
7
Evaluation of new broth media for microdilution antibiotic susceptibility testing of Lactobacilli, Pediococci, Lactococci, and Bifidobacteria.用于乳酸杆菌、片球菌、乳球菌和双歧杆菌微量稀释抗生素敏感性试验的新型肉汤培养基的评估
Appl Environ Microbiol. 2005 Dec;71(12):8982-6. doi: 10.1128/AEM.71.12.8982-8986.2005.
8
In vitro activities of daptomycin, vancomycin, quinupristin- dalfopristin, linezolid, and five other antimicrobials against 307 gram-positive anaerobic and 31 Corynebacterium clinical isolates.达托霉素、万古霉素、奎奴普丁-达福普汀、利奈唑胺及其他五种抗菌药物对307株革兰氏阳性厌氧菌和31株棒状杆菌临床分离株的体外活性。
Antimicrob Agents Chemother. 2003 Jan;47(1):337-41. doi: 10.1128/AAC.47.1.337-341.2003.
9
Lipoteichoic acid as a new target for activity of antibiotics: mode of action of daptomycin (LY146032).脂磷壁酸作为抗生素活性的新靶点：达托霉素（LY146032）的作用模式。
Antimicrob Agents Chemother. 1990 Jun;34(6):1220-6. doi: 10.1128/AAC.34.6.1220.
本文引用的文献
1
Deficient autolytic enzyme activity in antibiotic-tolerant lactobacilli.抗生素耐受性乳酸杆菌中自溶酶活性不足。
Infect Immun. 1982 May;36(2):582-5. doi: 10.1128/iai.36.2.582-585.1982.
2
In vitro activity of paldimycin (U-70138F) against gram-positive bacteria isolated from patients with cancer.帕地霉素（U-70138F）对从癌症患者中分离出的革兰氏阳性菌的体外活性。
Antimicrob Agents Chemother. 1987 Apr;31(4):650-2. doi: 10.1128/AAC.31.4.650.
3
In vitro susceptibility of gram-positive cocci to paldimycin.革兰氏阳性球菌对帕地霉素的体外敏感性
Antimicrob Agents Chemother. 1987 Jan;31(1):104-7. doi: 10.1128/AAC.31.1.104.
4
Antimicrobial activity and spectrum of LY146032, a lipopeptide antibiotic, including susceptibility testing recommendations.脂肽抗生素LY146032的抗菌活性与谱，包括药敏试验建议。
Antimicrob Agents Chemother. 1987 Apr;31(4):625-9. doi: 10.1128/AAC.31.4.625.
5
Effect of calcium on in vitro activity of LY146032 against Clostridium difficile.钙对LY146032体外抗艰难梭菌活性的影响。
Antimicrob Agents Chemother. 1987 Mar;31(3):461-2. doi: 10.1128/AAC.31.3.461.
6
In vitro activity of a new cyclic lipopeptide antibiotic, LY146032, against gram-positive clinical bacteria.新型环脂肽抗生素LY146032对革兰氏阳性临床细菌的体外活性
Antimicrob Agents Chemother. 1987 Mar;31(3):455-7. doi: 10.1128/AAC.31.3.455.
7
In vitro activity of LY146032, a new lipopeptide antibiotic, against gram-positive cocci.新型脂肽抗生素LY146032对革兰氏阳性球菌的体外活性
Antimicrob Agents Chemother. 1987 Feb;31(2):340-2. doi: 10.1128/AAC.31.2.340.
8
Antistaphylococcal activity of a cyclic peptide, LY146032, and vancomycin.环肽LY146032和万古霉素的抗葡萄球菌活性。
Antimicrob Agents Chemother. 1986 Dec;30(6):938-9. doi: 10.1128/AAC.30.6.938.
9
In vitro activity of LY146032 against staphylococci, streptococci, and enterococci.LY146032对葡萄球菌、链球菌和肠球菌的体外活性。
Antimicrob Agents Chemother. 1986 Nov;30(5):781-4. doi: 10.1128/AAC.30.5.781.
10
In vitro and in vivo activity of LY 146032, a new cyclic lipopeptide antibiotic.新型环脂肽抗生素LY 146032的体外和体内活性
Antimicrob Agents Chemother. 1986 Oct;30(4):532-5. doi: 10.1128/AAC.30.4.532.
Zotero 插件